Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
ADT and dementia in prostate cancer
Deka R et al. JAMA Oncol. 2018 Oct 11. doi: 10.1001/jamaoncol.2018.4423.
Key clinical point: In contrast with other recent investigations in prostate cancer, researchers found no link between androgen deprivation therapy (ADT) and development of dementia.
Major finding: No significant association was found between use of ADT and development of any dementia (subdistribution hazard ratio [SHR], 1.04; 95% CI, 0.94-1.16; P = .43).
Study details: Observational cohort study of more than 45,000 veterans with nonmetastatic prostate cancer treated with radiotherapy with or without ADT.
Disclosures: This study was funded by grants from the University of California San Diego Center for Precision Radiation Medicine. Dr. Deka and coauthors reported no conflict of interest disclosures related to the work.
Deka R et al. JAMA Oncol. 2018 Oct 11. doi: 10.1001/jamaoncol.2018.4423.